T. Rowe Price Investment Management (PRME) discloses 3.3% Prime Medicine stake

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reported beneficial ownership of 5,995,183 shares of Prime Medicine Inc. common stock, representing 3.3% of the class as of 12/31/2025. The firm has sole voting and dispositive power over all of these shares.

The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Prime Medicine. The filer also states that this report should not be construed as an admission that it is the beneficial owner of these securities.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PRIME MEDICINE INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

74168J101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74168J101

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,995,183.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,995,183.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,995,183.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PRIME MEDICINE INC
(b)	Address of issuer's principal executive offices: 60 FIRST ST., CAMBRIDGE, MA, 2141
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 74168J101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5995183
(b)	Percent of class: 3.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5995183
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5995183
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026

FAQ

What stake does T. Rowe Price Investment Management hold in PRME?

T. Rowe Price Investment Management, Inc. reports beneficial ownership of 5,995,183 shares of Prime Medicine Inc. common stock, representing 3.3% of the class as of December 31, 2025, according to the Schedule 13G/A filing.

Does T. Rowe Price Investment Management seek control of Prime Medicine (PRME)?

The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Prime Medicine, nor in connection with any transaction intended to have that effect.

What voting power does T. Rowe Price have over PRME shares?

T. Rowe Price Investment Management, Inc. reports sole voting power over 5,995,183 Prime Medicine common shares and no shared voting power. It also has sole dispositive power over the same number of shares, with no shared dispositive power reported.

Why did T. Rowe Price file a Schedule 13G/A for PRME?

The Schedule 13G/A reflects T. Rowe Price Investment Management, Inc.’s beneficial ownership of 3.3% of Prime Medicine’s common stock as of December 31, 2025, and confirms the position is held in the ordinary course, not to influence control of the company.

Does T. Rowe Price admit beneficial ownership of PRME shares in this filing?

The filing explicitly states that T. Rowe Price Investment Management, Inc. denies beneficial ownership of the securities referenced and that the submission should not be construed as an admission of beneficial ownership, despite reporting the position for regulatory purposes.

What percentage threshold does T. Rowe Price report for PRME ownership?

T. Rowe Price Investment Management, Inc. reports ownership of 5 percent or less of Prime Medicine’s common stock, specifically 3.3% of the class, which is below the 5% threshold commonly associated with more extensive ownership reporting obligations.